Marco Timmers, Ph.D., CEO – Byondis discusses Byondis develops new biological and chemical entities, a proprietary linker-drug platform to generate multiple novel ADCs
https://www.biospace.com/article/byondis-initiates-phase-ii-study-of-antibody-drug-conjugate-vic-trastuzumab-duocarmazine-in-advanced-endometrial-cancer-/
Advertisement